Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 12/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 12/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 12/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 10/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 10/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 10/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 10/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 3/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235750 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL8235515 | 0.89 | GABRG2 (0.81) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL13321576 | 0.88 | GABRG2 (0.78) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL8238208 | 0.87 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL8238213 | 0.87 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL17088109 | 0.87 | GABRG2 (0.77) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL13835544 | 0.86 | GABRG2 (0.81) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL17088108 | 0.84 | GABRG2 (0.78) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL13353376 | 0.84 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL10964002 | 0.84 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024229174-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | claimed |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260033761-A1 | CHARACTERISATION OF NEUROLOGICAL DYSFUNCTION | HOFFMANN LA ROCHE (US) | 2026-02-05 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| EP-3856342-B1 | BICYCLIC DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2025-12-10 | — | — | EP | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | disclosed |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | disclosed |
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-7595395-B2 | Gabaergic agents to treat memory deficits | WISYS TECHNOLOGY FOUNDATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595395-B2 | Gabaergic agents to treat memory deficits | WISYS TECHNOLOGY FOUNDATION (US) | 2009-09-29 | — | — | US | disclosed |
| WO-2007018660-A2 | GABAERGIC IMIDAZOBENZODIAZEPINE DERIVATIVES TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-11-16 | — | — | US | disclosed |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | GABRA5, GABRA6, GABRB1 | GABRG2 15/4885GABRB3 6/4885GABRA5 1/4885 |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | GABRG2 1092/4885GABRB3 387/4885GABRA5 1254/4885 |
| US-20260033761-A1 | CHARACTERISATION OF NEUROLOGICAL DYSFUNCTION | PMP22, PARK7, NCS1 | GABRG2 425/4885GABRB3 331/4885GABRA5 101/4885 |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | GABBR1, GABBR2, GABRB2 | GABRG2 14/4885GABRB3 9/4885GABRA5 5/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | GABRG2 17/4885GABRB3 12/4885GABRA5 9/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | GABRG2 1329/4885GABRB3 342/4885GABRA5 1883/4885 |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | GABRG2 13/4885GABRB3 8/4885GABRA5 9/4885 |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | GABRA5, GABRA6, GABRA1 | GABRG2 16/4885GABRB3 10/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.